Abstract
Phospholipases A2 (PLA2) are enzymes of high medical scientific interest due to their involvement in a large number of human inflammatory diseases. PLA2 constitute a diverse family of enzymes which catalyses the hydrolysis of the sn-2 ester bond in glycerophospholipids and exhibit a wide range of physiological and pathological effects. The ubiquitous nature of PLA2 highlights the important role they play in many biological processes, as cell signaling and cell growth, including the generation of proinflammatory lipid mediators such as prostaglandin and leukotrienes, regulation of lipid mediators. The activity and expression of several PLA2 isoforms are increased in several human cancers, suggesting that these enzymes have a central role in both tumor development and progression and can be targets for anti-cancer drugs. On the other hand, some PLA2 isolated from Viperidae venoms are capable to induce antitumoral activity. In summary PLA2 from snake venoms can be a new class of anticancer agents and provide new molecular and biological insights of cancer development.
Keywords: Snake venom, phospholipase A2, antitumor effect, VRCTC-310
Protein & Peptide Letters
Title: Snake Venom Phospholipases A2: A New Class of Antitumor Agents
Volume: 16 Issue: 8
Author(s): Renata S. Rodrigues, Luiz Fernando M. Izidoro, Robson J. de Oliveira Jr., Andreimar M. Soares, Veridiana M. Rodrigues and Suely V. Sampaio
Affiliation:
Keywords: Snake venom, phospholipase A2, antitumor effect, VRCTC-310
Abstract: Phospholipases A2 (PLA2) are enzymes of high medical scientific interest due to their involvement in a large number of human inflammatory diseases. PLA2 constitute a diverse family of enzymes which catalyses the hydrolysis of the sn-2 ester bond in glycerophospholipids and exhibit a wide range of physiological and pathological effects. The ubiquitous nature of PLA2 highlights the important role they play in many biological processes, as cell signaling and cell growth, including the generation of proinflammatory lipid mediators such as prostaglandin and leukotrienes, regulation of lipid mediators. The activity and expression of several PLA2 isoforms are increased in several human cancers, suggesting that these enzymes have a central role in both tumor development and progression and can be targets for anti-cancer drugs. On the other hand, some PLA2 isolated from Viperidae venoms are capable to induce antitumoral activity. In summary PLA2 from snake venoms can be a new class of anticancer agents and provide new molecular and biological insights of cancer development.
Export Options
About this article
Cite this article as:
Rodrigues S. Renata, Izidoro M. Luiz Fernando, de Oliveira Jr. J. Robson, Soares M. Andreimar, Rodrigues M. Veridiana and Sampaio V. Suely, Snake Venom Phospholipases A2: A New Class of Antitumor Agents, Protein & Peptide Letters 2009; 16 (8) . https://dx.doi.org/10.2174/092986609788923266
DOI https://dx.doi.org/10.2174/092986609788923266 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Histone Deacetylase Inhibitors: Recent Insights from Basic to Clinical Knowledge & Patenting of Anti-Cancer Actions
Recent Patents on Anti-Cancer Drug Discovery The Current and Future Therapies for Human Osteosarcoma
Current Cancer Therapy Reviews The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors
Mini-Reviews in Medicinal Chemistry New Approaches to Target Cancer Stem Cells: Current Scenario
Mini-Reviews in Medicinal Chemistry Inhibition of Anti-Apoptotic Bcl-2 Family Proteins by Natural Polyphenols New Avenues for Cancer Chemoprevention and Chemotherapy
Current Pharmaceutical Design Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design The Roles of Endoplasmic Reticulum Stress in the Pathophysiological Development of Cartilage and Chondrocytes
Current Pharmaceutical Design Modulation of MMPs by Cell Surface Integrin Receptor α5β1
Anti-Cancer Agents in Medicinal Chemistry Allelic Imbalances of the egfr Gene as Key Events in Breast Cancer Progression – the Concept of Committed Progenitor Cells
Current Cancer Drug Targets The Functions of Histone Modification Enzymes in Cancer
Current Protein & Peptide Science Aggrecanase: The Family and Its Inhibitors
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Current Cancer Drug Targets The Role of MDCT in Craniocervical Junction Pathologies: Pictorial Review
Current Medical Imaging Evaluation of the Ability of an Organic Derivative of Ruthenium(II) to Reinforce the Cytotoxicity of Fast Neutron Against Malignant Cells in Culture
Letters in Drug Design & Discovery Pathology and Development - Developmental Systems for Target Validation and Drug Screening in Osteoarthritis
Drug Design Reviews - Online (Discontinued) The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging Mesenchymal Stem Cells in Cartilage Repair: State of the Art and Methods to monitor Cell Growth, Differentiation and Cartilage Regeneration
Current Medicinal Chemistry Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging